EP1646353A4 - Proteines de fusion destinees au traitement du systeme nerveux central - Google Patents

Proteines de fusion destinees au traitement du systeme nerveux central

Info

Publication number
EP1646353A4
EP1646353A4 EP04776038A EP04776038A EP1646353A4 EP 1646353 A4 EP1646353 A4 EP 1646353A4 EP 04776038 A EP04776038 A EP 04776038A EP 04776038 A EP04776038 A EP 04776038A EP 1646353 A4 EP1646353 A4 EP 1646353A4
Authority
EP
European Patent Office
Prior art keywords
cns
treatment
fusion proteins
fusion
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04776038A
Other languages
German (de)
English (en)
Other versions
EP1646353A2 (fr
Inventor
Elliott A Gruskin
Anthony O Caggiano
Jennifer Iaci
Michael P Zimber
Gargi Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Priority to ES17164945T priority Critical patent/ES2831031T3/es
Priority to EP10184697.0A priority patent/EP2354155B1/fr
Priority to EP17164945.2A priority patent/EP3210999B1/fr
Publication of EP1646353A2 publication Critical patent/EP1646353A2/fr
Publication of EP1646353A4 publication Critical patent/EP1646353A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP04776038A 2003-05-16 2004-05-17 Proteines de fusion destinees au traitement du systeme nerveux central Ceased EP1646353A4 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES17164945T ES2831031T3 (es) 2003-05-16 2004-05-17 Proteínas de fusión para el tratamiento del CNS
EP10184697.0A EP2354155B1 (fr) 2003-05-16 2004-05-17 Protéines de fusion pour le traitement du SNC
EP17164945.2A EP3210999B1 (fr) 2003-05-16 2004-05-17 Protéines de fusion pour le traitement du snc

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47123603P 2003-05-16 2003-05-16
US47130003P 2003-05-16 2003-05-16
US47123903P 2003-05-16 2003-05-16
US47124003P 2003-05-16 2003-05-16
US47437203P 2003-05-29 2003-05-29
PCT/US2004/015661 WO2004110359A2 (fr) 2003-05-16 2004-05-17 Proteines de fusion destinees au traitement du systeme nerveux central

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP17164945.2A Division EP3210999B1 (fr) 2003-05-16 2004-05-17 Protéines de fusion pour le traitement du snc
EP10184697.0A Division EP2354155B1 (fr) 2003-05-16 2004-05-17 Protéines de fusion pour le traitement du SNC

Publications (2)

Publication Number Publication Date
EP1646353A2 EP1646353A2 (fr) 2006-04-19
EP1646353A4 true EP1646353A4 (fr) 2008-06-04

Family

ID=33556640

Family Applications (3)

Application Number Title Priority Date Filing Date
EP10184697.0A Expired - Lifetime EP2354155B1 (fr) 2003-05-16 2004-05-17 Protéines de fusion pour le traitement du SNC
EP04776038A Ceased EP1646353A4 (fr) 2003-05-16 2004-05-17 Proteines de fusion destinees au traitement du systeme nerveux central
EP17164945.2A Expired - Lifetime EP3210999B1 (fr) 2003-05-16 2004-05-17 Protéines de fusion pour le traitement du snc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10184697.0A Expired - Lifetime EP2354155B1 (fr) 2003-05-16 2004-05-17 Protéines de fusion pour le traitement du SNC

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP17164945.2A Expired - Lifetime EP3210999B1 (fr) 2003-05-16 2004-05-17 Protéines de fusion pour le traitement du snc

Country Status (7)

Country Link
EP (3) EP2354155B1 (fr)
JP (5) JP5399612B2 (fr)
AU (1) AU2004247025B8 (fr)
CA (1) CA2525782C (fr)
ES (1) ES2831031T3 (fr)
MX (2) MX351062B (fr)
WO (1) WO2004110359A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666852B2 (en) * 2002-04-22 2010-02-23 Agenta Biotechnologies, Inc. Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide
WO2004108069A2 (fr) 2002-05-04 2004-12-16 Acorda Therapeutics, Inc. Compositions et methodes visant a favoriser l'excroissance neuronale
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP3211084B1 (fr) 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central
CA2566731C (fr) * 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Procedes de purification de la chondroitinase et formulations stables de cette derniere
CA2623635C (fr) 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions et procedes d'utilisation de mutants des chondroitinases abci
WO2007132481A2 (fr) * 2006-05-12 2007-11-22 Bharat Biotech International Limited Nouvelles molécules thrombolytiques et procédé associé
WO2007136042A1 (fr) 2006-05-19 2007-11-29 Aichi Prefecture Agent de traitement de lésions cérébrales
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
ES2437110T3 (es) * 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
WO2008149428A1 (fr) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. Agent thérapeutique et agent préventif pour une maladie auto-immune, une inflammation et une maladie nerveuse
AU2015200220A1 (en) * 2008-02-29 2015-02-12 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
JP5697455B2 (ja) * 2008-02-29 2015-04-08 アコーダ セラピューティクス インコーポレイテッド グリア成長因子２の所望の血漿レベルを達成するための方法
JP2013535507A (ja) * 2010-08-13 2013-09-12 ジョージタウン ユニバーシティ Ｇｇｆ２および使用方法
US9144601B2 (en) 2011-09-15 2015-09-29 Seikagaku Corporation Skeletal muscle regeneration promoter
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
US11396529B2 (en) 2020-11-12 2022-07-26 National Sun Yat-Sen University Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062067A1 (fr) * 1999-02-28 2000-10-19 Washington University Nouvelles molecules de transduction et leurs procedes d'utilisation
US6171575B1 (en) * 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
WO2002055684A2 (fr) * 2001-01-09 2002-07-18 Univ Iowa Res Found Proteines a ptd modifie
WO2002083179A2 (fr) * 2001-04-12 2002-10-24 Bioaxone Therapeutique Inc. Proteines de fusion
WO2003100031A2 (fr) * 2002-05-20 2003-12-04 Board Of Regents, The University Of Texas System Procedes et compositions pour la delivrance d'enzymes et de molecules d'acide nucleique dans le cerveau, l'os, et autres tissus
WO2004017044A2 (fr) * 2002-08-15 2004-02-26 Acorda Therapeutics, Inc. Proteine chimere

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
EP0702715A4 (fr) * 1993-04-23 2000-01-19 American Cyanamid Co CLONAGE ET EXPRESSION DE GENES DE CHONDROITINASE I ET II A PARTIR DE $i(P. VULGARIS)
AU1176595A (en) * 1993-11-12 1995-05-29 International Technology Management Associates, Ltd. Methods of repairing connective tissues
JPH07316068A (ja) * 1994-05-25 1995-12-05 Canji Inc 腫瘍サプレッサー融合タンパク質
GB9622500D0 (en) * 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
WO2000055207A1 (fr) * 1999-03-16 2000-09-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, The National Institutes Of Health Nouvelle proteine chimere permettant de prevenir et de traiter l'infection due au vih
SE9901428D0 (sv) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
BRPI0011407B8 (pt) * 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
WO2001039795A2 (fr) * 1999-12-02 2001-06-07 Ibex Technologies, Inc. Attenuation de la proliferation de fibroblastes
CA2455827C (fr) * 2001-08-13 2015-06-09 University Of Florida Research Foundation, Inc. Materiaux et procedes de greffes nerveuses comprenant la degradation de la proteoglycane de chondroitine sulfate
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171575B1 (en) * 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
WO2000062067A1 (fr) * 1999-02-28 2000-10-19 Washington University Nouvelles molecules de transduction et leurs procedes d'utilisation
WO2002055684A2 (fr) * 2001-01-09 2002-07-18 Univ Iowa Res Found Proteines a ptd modifie
WO2002083179A2 (fr) * 2001-04-12 2002-10-24 Bioaxone Therapeutique Inc. Proteines de fusion
WO2003100031A2 (fr) * 2002-05-20 2003-12-04 Board Of Regents, The University Of Texas System Procedes et compositions pour la delivrance d'enzymes et de molecules d'acide nucleique dans le cerveau, l'os, et autres tissus
WO2004017044A2 (fr) * 2002-08-15 2004-02-26 Acorda Therapeutics, Inc. Proteine chimere

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"ROUTE OF ADMINISTRATION - FDA", 11 January 2006 (2006-01-11), XP055243674 *
BRADBURY E J ET AL: "Chondroitinase ABC promotes functional recovery after spinal cord injury", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 416, 11 April 2002 (2002-04-11), pages 636 - 640, XP002245003, ISSN: 0028-0836 *
FROM WIKIPEDIA: "Route of administration", 5 January 2016 (2016-01-05), XP055243671 *
MCGEE A W ET AL: "The Nogo-66 receptor: focusing myelin inhibition of axon regeneration", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 4, April 2003 (2003-04-01), pages 193 - 198, XP004418152, ISSN: 0166-2236 *

Also Published As

Publication number Publication date
WO2004110359A2 (fr) 2004-12-23
CA2525782C (fr) 2019-02-05
EP2354155A2 (fr) 2011-08-10
AU2004247025A1 (en) 2004-12-23
JP5399612B2 (ja) 2014-01-29
JP2020111578A (ja) 2020-07-27
MX351062B (es) 2017-09-29
JP2017125035A (ja) 2017-07-20
JP2007516229A (ja) 2007-06-21
EP3210999A1 (fr) 2017-08-30
EP3210999B1 (fr) 2020-08-26
EP1646353A2 (fr) 2006-04-19
WO2004110359A9 (fr) 2006-02-16
JP2013049677A (ja) 2013-03-14
JP2014221793A (ja) 2014-11-27
WO2004110359A3 (fr) 2006-08-17
JP5656314B2 (ja) 2015-01-21
EP2354155B1 (fr) 2017-05-03
ES2831031T3 (es) 2021-06-07
JP6141571B2 (ja) 2017-07-12
EP2354155A3 (fr) 2011-09-07
AU2004247025B2 (en) 2011-06-23
MXPA05012306A (es) 2006-04-18
CA2525782A1 (fr) 2004-12-23
AU2004247025B8 (en) 2011-06-30
JP6913428B2 (ja) 2021-08-04

Similar Documents

Publication Publication Date Title
IL257192B (en) Cleaning proteins
IL166751A0 (en) Modified transferin-antibody fusion proteins
EP1688439A4 (fr) Composition proteique hybride
IL173456A0 (en) Process for the preparation of 4-amino-3-quinolinecarbonitriles
HK1096096A1 (en) Novel fused pyrrolocarbazoles
IL176385A0 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
EP1646353A4 (fr) Proteines de fusion destinees au traitement du systeme nerveux central
IL176326A0 (en) Process for the production of proteins
EP1549343A4 (fr) Methode de traitement de la nephrite faisant intervenir des anticorps anti-pdgf-dd
IL175743A0 (en) Process for the preparation of thiazolopyrimidines
EP1578774A4 (fr) Purification de proteines
SI1656455T1 (sl) Postopek za čiščenje rekombinantnih polipeptidov
GB0200689D0 (en) Fusion proteins
HK1095145A1 (en) Process for the preparation of n-arylmorpholinones n-
PL371583A1 (en) Process for the preparation of 7alpha-methylsteroids
SG111997A1 (en) Improved process for the preparation of polyalkylphenoxyaminoalkanes
HK1087111A1 (en) Process for the preparation of nicotinaldehydes
IL164788A0 (en) Process for the preparation of 3-isochromanone
GB0522915D0 (en) Methods for recombinant immunoglobulin treatment
PL376745A1 (pl) Proces oczyszczania białek wiążących TNF przy użyciu IMAC
GB0311108D0 (en) Proteins
HU0300255D0 (en) Process for the preparation of 2-phenyl-4-methyl-1-tosil-piperazine
SI1673365T1 (sl) Postopek za pripravo Z-flupentiksola.
AU2003290331A8 (en) Protein purification means
SI1395580T1 (en) Method for the purification of triazolylmethylepoxides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051214

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/06 20060101AFI20061005BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GRUSKIN, ELLIOTT, A.

Inventor name: IACI, JENNIFER

Inventor name: ROY, GARGI

Inventor name: ZIMBER, MICHAEL, P.

Inventor name: CAGGIANO, ANTHONY, O.

A4 Supplementary search report drawn up and despatched

Effective date: 20080506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/51 20060101ALI20080425BHEP

Ipc: C12N 9/88 20060101ALI20080425BHEP

Ipc: C12P 21/06 20060101AFI20061005BHEP

Ipc: C07K 14/475 20060101ALI20080425BHEP

17Q First examination report despatched

Effective date: 20080905

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20160923